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ABSTRACT
Clinical trials of interleukin 1α (IL-1α) and IL-1β
have been completed that assess the toxicities of these
cytokines as well as their hematopoietic and antitumor
effects. Both forms of IL-1 recognize the same cell sur-
face receptors and have similar toxicities and similar
biological activities. Toxicities including fever, flu-like
symptoms and dose-limiting hypotension can be severe
yet manageable, and IL-1 can be given safely to human
cancer patients. Most toxicities and biological effects
appear to be dose-related. IL-1 alone has little antitu-
mor activity against melanoma, renal cell carcinomas
or other malignancies. The hematopoietic effects,
including megakaryocytopoietic effects, are modest
and are probably not worth the toxicity necessary to
achieve them. However, IL-1 seems to endow cer-
tain progenitor cells with responsiveness to other
hematopoietic cytokines including colony-stimulat-
ing factors and IL-3. One potential application of IL-
1 is to help expand bone marrow ex vivo following stem
cell harvest, which could allow further chemotherapy
dose escalations in chemotherapy-sensitive tumors. 
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INTRODUCTION
In recent years, biologic response modifiers have been stud-
ied in an effort to expand the oncologist’s arsenal in the battle
against cancer. Interleukin 1 (IL-1) was one of the first biologic
response modifiers identified, but clinical studies of interferon
(IFN), IL-2, tumor necrosis factor (TNF) and colony stimulating
factors (CSFs) preceded IL-1 trials. IL-1 was first identified as
an endogenous pyrogen during research on fever dating back to
the 1940s [1]. This protein was found in acute granulocytic exu-
date fluid, and when injected into humans or animals, it pro-
duced fever. In the 1970s, the purified product demonstrated
other effects including induction of neutrophilia, apparent
colony stimulating activity, augmentation of thymocyte and T
cell proliferation to mitogens, and induction of nonspecific resis-
tance to infection [2]. IL-1α and IL-1β were both cloned and
sequenced in 1984 [3]. Both forms of IL-1 recognize the same
cell surface receptors and have similar biological activity, but
they are distinct gene products with only 27% homology [4]. 
The effects of IL-1 are multiple, involving immunomodu-
lation, inflammation, wound healing, hematopoiesis, metabo-
lism and the endocrine system [2]. IL-1 also has a number of
properties potentially useful in the treatment of cancer, includ-
ing direct antiproliferative activity against certain human
tumor cell lines and several murine tumors [5, 6], the activa-
tion of effector cells in vitro [7-9], the ability to induce hemor-
rhagic necrosis and the inhibition of tumor angiogenesis [10],
and the induction of secondary cytokines that may have direct
antiproliferative or immunostimulatory activities [2, 11]. In
addition, IL-1 has the capacity to protect and restore the bone
marrow from radiation or chemotherapy-induced injury [12,
13]; it can stimulate proliferation of multipotential bone mar-
row progenitors in the presence of other colony stimulating
factors [14] and also has immunostimulating properties that
might be helpful in the treatment of cancer patients at high risk
for infection [15].
Phase I studies of IL-1 in cancer patients were begun in
1989 to determine
the maximum toler-
ated dose (MTD) by
various schedules
and routes of admin-
istration. Phase II tri-
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been conducted. IL-1 has also been tested in combination
with chemotherapy to determine the
hematopoietic effects of this agent. In
total, there have been at least 20
reported clinical trials of IL-1 con-
ducted during the late 1980s and
early 1990s. This article will summa-
rize the results of these trials.
PHASE I TRIALS
The common side effects of
IL-1 observed in the phase I trials
are listed in Table 1 and the trials
are summarized in Table 2. Patients
experienced a number of flu-like
symptoms including chills, rigors,
fever, nausea, vomiting, fatigue,
headache, myalgia and mild som-
nolence [16]. Fever, chills and rig-
ors occurred in almost every
patient, but were not dose-limiting.
At higher doses of IL-1α, some
patients experienced weight gain,
dyspnea and pulmonary infiltrates
consistent with a pulmonary capillary leak phenomenon.
However, these patients did not exhibit the severe pul-
monary toxicities commonly observed with high-dose
IL-2 therapy. Severe abdominal pain without diarrhea and
more severe central nervous system toxicity were
observed in a few patients treated at higher doses of IL-1.
Investigators at Memorial Sloan-Kettering Cancer Center
studied escalating doses (from 0.002 µg/kg to 0.1 µg/kg) of
recombinant human (rHu) IL-1β (Syntex; Palo Alto, CA)
given by short i.v. infusion for two days in patients with gas-
trointestinal cancer [17]. Toxicities included fever, rigors and
headache in the majority of patients. Hypotension was the
dose-limiting toxicity and was observed in three of five
patients at the highest dose level (0.1 µg/kg).
The Biological Response Modifiers Program (BRMP)
of the National Cancer Institute (NCI) conducted a phase I
trial of IL-1α (Dainippon; Osaka, Japan) given by i.v. infu-
sion over 15 min for seven days in patients with advanced
malignancies [16]. An inpatient MTD with maximal sup-
portive measures including blood pressure support with
pressors was determined to be 0.3 µg/kg. A group of patients
was also treated with indomethacin and IL-1α to determine
if the toxicity of IL-1α could be ameliorated by inhibitors of
prostaglandin synthesis as suggested by animal studies [18];
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Table 1. Common side effects
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Table 2. Published phase I trials
Investigators Type of IL-1 Doses Route Schedule MTD
Crown et al. [17] IL-1β 0.002 µg/kg-0.1 µg/kg i.v. 0.068 µg/kg
(MSKCC) (Syntex) over 30 min (without pressors)
q.d. × 2 days
Smith et al. [19] IL-1α 0.01 µg/kg-1.0 µg/kg i.v. 0.3 µg/kg
(BRMP/NCI) (Dainippon) over 15 min (with pressors for blood
q.d. × 7 days pressure support)
Steis et al. [20] IL-1β 0.01 µg/kg-1.0 µg/kg i.v. 0.3 µg/kg
(BRMP/NCI) (Syntex) over 15 min (with pressors)
q.d. × 7 days
Dennis et al. [21] IL-1α 0.08 µg/m2-5.0 µg/m2 i.v. 2 µg/m2
(NYUMC) (Immunex) over 2 h (without pressors)
q.d. × 5 days
Kanz et al. [22] IL-1β 10-100 ng/kg (MTD not reached)
(Univ. of Frieburg (Syntex) SQ
Germany) q.d. × 7 Days
Janik et al. [23] IL-1α 0.001 µg/kg-0.1 µg/kg (MTD not reached)
(BRMP/NCI) (Dainippon) intratumoral injection
(SQ/cut.)
q.d. × 5 days
Abbreviations: MTD = maximum tolerated dose
MSKCC = Memorial Sloan-Kettering Cancer Center
BRMP/NCI = Biological Response Modifiers Program/National Cancer Institute
NYUMC = New York University Medical Center
however, the tolerance of IL-1α was not improved [19]. In
this study, somnolence was noted after IL-1α treatment in
several patients, and may have been related to the medica-
tions given for chills or nausea. Electroencephalograms
obtained after the first dose showed diffuse slowing consis-
tent with a metabolic encephalopathy. One patient treated at
the highest dose level (1.0 µg/kg plus indomethacin) experi-
enced severe somnolence, agitation and confusion; all
symptoms resolved within 48 h after IL-1α was stopped.
Another patient treated at 0.3 µg/kg plus indomethacin was
observed to have confusion and delusional ideation; this tox-
icity resolved soon after treatment was discontinued. One
patient treated with 0.3 µg/kg IL-1α plus indomethacin suf-
fered a myocardial infarction after his fourth dose accompa-
nied by ventricular tachycardia that was cardioverted
successfully.
Cardiovascular effects were the most worrisome side
effects that interfered with dose escalation in all the clinical
trials of IL-1 and were well described in the IL-1α trial
[16]. Systolic blood pressure (BP) rose during the first 30
min after treatment but decreased consistently thereafter,
reaching 90 mm Hg or lower between 3 h and 5 h after
treatment with the higher doses. Hypotension was managed
with boluses of normal saline; however, at dose levels ≥ 0.3
mcg/kg, it was necessary to support the BP with i.v.
phenylephrine, dopamine or both. The hypotension resulted
from a marked decrease in the systemic vascular resistance
(SVR) and not from a decline in cardiac output. IL-1α treat-
ment resulted in a significant drop in SVR, which in 3 h had
decreased by 50% or more (Fig. 1). Heart rate and cardiac
output rose in a compensatory fashion in response to the
drop in BP and SVR. The cardiac output failed to increase
further when patients received fluid loading, and a decrease
in the ejection fraction was observed in one patient at the
highest dose of IL-1. The cardiovascular effects of IL-1α
were the same as those observed in septic shock, i.e., tachy-
cardia, hypotension, decreased systemic vascular resistance
and some degree of myocardial dysfunction. 
As described in Table 3, IL-1 treatment in all studies had
both early and late effects on the bone marrow and peripheral
blood. IL-1α treatment increased the number of granulocytes
in the peripheral blood 4 h after treatment, consistent with a
demargination effect; however, the high number of bands
that appeared in the peripheral blood indicates that IL-1 also
caused an egress of cells from the maturation-storage com-
partment of the marrow. In the Memorial Sloan-Kettering
and BRMP studies, significant increases in the platelet
counts were observed one to two weeks after treatment, and
increased megakaryocytes were also observed in bone mar-
row biopsies performed after seven days of IL-1 treatment in
the IL-1 study at the BRMP. Dose-related increases in serum
IL-6 levels also were noted after IL-1 treatment in both
studies [16, 17].
The BRMP also conducted a phase I trial of IL-β
(Syntex) with a study design and endpoints exactly the same
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Figure 1. (Left) Mean systolic blood pressure (▫ ) and heart rate () of three patients after their first dose of 0.3 µg/kg IL-1α. (Right)
Mean systemic vascular resistance (SVR) of these same patients.
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as for the IL-1α study [20]. Toxicities observed in this trial
were similar to those described for IL-1α, and the MTDs
were identical as well. Uncommon toxicities included
hypertension accompanied by pulmonary edema in one
patient at the 0.1 µg/kg dose level, and atrial fibrillation in
one patient treated at the 0.3 µg/kg dose level. Dose-limiting
toxicity was reached at the 1.0 µg/kg dose level where one
patient had severe long-lasting hypotension, and another
patient developed bronchospasm.
Investigators at New York University Medical
Center also conducted a phase I trial of IL-1α (Immunex;
Seattle, WA) using a 2-h i.v. infusion for five days [21].
The dose-limiting toxicity was hypotension requiring i.v.
fluids and occurred at the 3 µg/m2 dose level (approxi-
mately 0.1 µg/kg). They defined the MTD as 2 µg/m2.
Other toxicities were similar to those observed in the
previously mentioned phase I trials. Hematopoietic
effects were also similar: increased granulocytes,
increased bone marrow cellularity and a delayed increase
in platelets. Although IL-1-mediated increases in bone
marrow progenitors were not seen, there was a signifi-
cant dose-dependent increase in the number of circulat-
ing granulocyte, macrophage, granulocyte-macrophage
and eosinophil colony forming units (CFUs) in the
peripheral blood prior to and at the end of the 2-h IL-1α
infusion on day 5. In this study, monocyte cytotoxicity
assays were performed using the HT29 colon cancer cell
line with and without the in vitro addition of IFN-γ.
IL-1α increased direct monocyte cytotoxicity and aug-
mented the monocyte cytotoxicity observed with the
addition of IFN-γ in vitro.
IL-1β (Syntex) by s.c. administration was tested in a
cohort of patients with advanced cancer [22]. Dose lev-
els of 10 to 100 ng/kg were delivered daily for seven
days. Toxicities were similar to IL-1β given intra-
venously; however, atrial fibrillation and an episode of
deep venous thrombosis were seen in the s.c. trial.
Dose-dependent increases in WBCs were seen lasting 12
to 14 days after treatment. Similarly, platelet counts
increased five to seven days after IL-1 treatment and
remained elevated for up to four weeks. 
The BRMP performed a trial of IL-1α injected into a
single s.c. or cutaneous lesion in melanoma patients once
daily for five days [23]. Groups of at least three patients
each were treated with IL-1α beginning with 0.001
µg/kg. The IL-1α dose was escalated by half-log incre-
ments between cohorts up to 0.1 µg/kg. Toxicity was rel-
atively minor with this method of administration. Fever
and chills were common but were grade 2 or less in all
but one patient. There was erythema at the site of IL-1α
injection in 8 of 15 patients.
COMBINATION IL-1 AND IL-2 PHASE I TRIALS
Some investigators combined IL-1 and IL-2 to enhance
cellular immune function. At the University of Chicago, can-
cer patients were treated with five dose levels of IL-1α
(Dainippon) by s.c. injection, ranging from 0.001 to 0.1
µg/kg/day, with IL-2 at 1.5 MU/m2/day [24]. Increases in nat-
ural killer cell activity from 1.3 to 22 times baseline were seen
in all patients; however, there was no relation of this finding to
IL-1 dose level. All patients displayed increases in granulo-
cytes, eosinophils and platelets. The peak granulocyte count
correlated with the IL-1 dose. Minor responses were seen in
one renal cell and one melanoma patient. 
A similar trial was performed with IL-1β (Syntex)
given by i.v. infusion over 30 min at doses from 0.005 to
0.2 µg/kg/day on four consecutive days. This IL-1 regimen
was combined with IL-2 at 0.1 µg/m2/day by continuous
infusion concurrent with the IL-1 administration [25].
These cycles were repeated weekly for eight weeks.
Treatment was well tolerated. Lymphokine activated killer
cell (LAK) activity in the peripheral blood was highest at the
lowest IL-1 dose level and decreased with increasing IL-1β
dose. The number of circulating CD56+ cells did increase in
a dose-dependent fashion with IL-1. Increases in the number
of CD25+ cells, CD45RO+ cells and monocyte tumor cell
cytolysis also were noted but had no relationship to IL-1β
dose. Complete and partial responses were seen in five of
the15 patients: colon cancer (3), renal cell carcinoma (1) and
melanoma (1). 
PHASE II TRIALS
IL-1α could have antitumor activity against melanoma
based on its direct antiproliferative activity in vitro against
human melanoma cell lines, its ability to induce IFNs and
IL-2 (both of which have activity alone and in combination
in melanoma patients) and its ability to enhance the activity
of cytotoxic T cells and other effector cells. It can also induce
hemorrhagic necrosis in some animal tumor models.
Investigators at Stanford University reported preliminary
results of a trial of IL-1β (Syntex) in melanoma patients [26].
Patients received doses ranging from 0.001 to 0.1 µg/kg i.v.
for five days every six weeks. Of nine evaluable patients,
there was one complete and two partial responses in patients
with nonvisceral sites of metastasis.
Metastatic melanoma patients were treated at the BRMP
with IL-1α (Dainippon) at 0.1 µg/kg i.v. over 15 min once
daily for seven days [27]. Indomethacin 50 mg p.o. or p.r.
was given starting 2 h before the first dose and continued
every 8 h during IL-1 treatment based on animal studies
demonstrating enhanced antitumor activity of the combina-
tion. Treatment was repeated once after a two-week rest.
Forty-nine patients were entered into this study; all were
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evaluable for response. Chills, fever, headache, nausea, vom-
iting and myalgia were common but were grade 1 or 2. Grade
3 hypotension requiring i.v. pressors (phenylephrine)
occurred in one-third of patients and was limited to the first
dose in all but two patients, who required pressors with their
first and second doses. All toxicities were worse with the first
dose and gradually improved during the therapy. Of the 14
evaluable patients with predominantly visceral metastases,
there were no partial or complete remissions. Of the 35
patients with predominantly nonvisceral metastatic disease,
there were four responses: one complete and three partial, for
a response rate of 11% (95% confidence interval: 5%-26%).
The duration of the complete response was 37+ months, and
the durations of the partial responses were each six months.
Redman et al. conducted a phase II trial of rIL-1β in
patients with metastatic renal cell carcinoma [28]. IL-1β
(Syntex) was administered at 50 ng/kg i.v. daily for five days
on a 28-day schedule. There were no complete or partial
responders among the 16 evaluable patients. Grades I and II
fever, rigors, hypotension and weight gain were typical tox-
icities. One patient had grade IV neurotoxicity (seizures)
and one had grade III somnolence. They also noted an
increase from mean pretreatment levels of soluble IL-2
receptor and IL-6 levels. Neutrophilic leukocytosis and mild
thrombocytosis were also observed.
TRIALS OF IL-1 AS A HEMATOPOIETIC AGENT
The dose escalation of many antineoplastic drugs is lim-
ited by granulocytopenia and thrombocytopenia. In vitro and
preclinical studies demonstrated that IL-1 induced the produc-
tion of many hematopoietic growth factors such as G-CSF,
GM-CSF, M-CSF and IL-6. IL-1 also acted synergistically
with these cytokines and growth factors to stimulate
hematopoiesis and promote the proliferation and differentia-
tion of hematopoietic progenitor cells in vitro [29-31]. In addi-
tion, IL-1 upregulated the expression of receptors for IL-1,
GM-CSF and IL-3 on hematopoietic progenitor cells [32].
Preclinical studies showed that IL-1 accelerated the recovery
of granulocytes and platelets when given after chemotherapy
or sublethal radiation, and it had a protective effect if given
before lethal radiation or chemotherapy [13, 33, 34]. Because
phase I studies showed IL-1 to have the ability to increase
granulocytes and platelets in cancer patients who had not
received chemotherapy, several investigators combined IL-1
with myelosuppressive chemotherapy regimens to test its abil-
ity to ameliorate granulocytopenia and thrombocytopenia 
following chemotherapy.
To determine if granulocyte recovery could be acceler-
ated by IL-1β, as suggested by animal models [17], investi-
gators at Memorial Sloan-Kettering gave two days of IL-1β
after three days of 5-fluorouracil (5-FU) at 833 µg/m2/day.
Patients had previously received a cycle of 5-FU alone and
were used as their own controls. IL-1β was escalated in
sequential cohorts of patients from 0.002 µg/kg to 0.1 µg/kg.
There was a trend toward fewer days of neutropenia after
IL-1β treatment; however, the difference did not reach statis-
tical significance. No thrombocytopenia resulted from the
5-FU treatment, so no conclusion about thrombopoietic
effects of IL-1β could be reached.
A clinical trial was performed at the BRMP combining
IL-1α with high-dose carboplatin to test if IL-1α could be
useful in ameliorating chemotherapy-induced thrombocy-
topenia [35]. One group of patients received IL-1α before
chemotherapy because preclinical studies indicated that IL-1
was capable of protecting the bone marrow from chemother-
apy- or radiation therapy-induced myelosuppression [13, 34].
IL-1α was given after chemotherapy to another group to test
its ability to promote hematopoietic recovery. The first-cycle
platelet counts of each of the eight patients in the control
group dropped below 100,000/µL with a nadir platelet count
that ranged from 5,000 to 56,000/µL (median 19,000/µL).
IL-1α treatment before carboplatin at 0.03, 0.10, and 0.30
µg/kg had no effect on the first-cycle platelet count nadir,
duration of thrombocytopenia, time to decline below, or time
to recover above 100,000 platelets/µL compared to the con-
trol group. IL-1α treatment after carboplatin at 0.03 and 0.1
µg/kg similarly had no effect. However, at 0.3 µg/kg IL-1α
after carboplatin, the median time to recovery of 100,000
platelets was 16 days compared to 23 days in the IL-1α
before carboplatin group and 21 days in the control group
(Fig. 2). In addition, two of the five patients treated with
IL-1α 0.1 µg/kg after carboplatin and three of the ten patients
treated with IL-1α 0.3 µg/kg after carboplatin had markedly
less thrombocytopenia after treatment, with mean platelet
nadirs of 165,000/µL (range 91,000-332,000/µL).
Vadhan-Raj and colleagues at M.D. Anderson Hospital
conducted a study of continuous i.v. infusion of IL-1α
(Immunex) after carboplatin 400 µg/m2 in patients with recur-
rent ovarian cancer [36]. During the first month, cohorts of
patients received four days of IL-1α alone at escalating doses
from 0.1 to 10.0 µg/m2/24 h (approximately 0.0025-0.25
µg/kg). During the second month, the patients were treated
with carboplatin 400 µg/m2 alone. Patients received carbo-
platin followed by IL-1α in the third month. Treatment with
IL-1α resulted in significantly fewer days of severe thrombo-
cytopenia (<100,000/µL or <50,000 platelets/µL) when the
third month was compared to the second month. A few
patients who had documented platelet nadirs at <100,000/µL
with carboplatin alone no longer had such declines with the
subsequent cycles that included IL-1α. The number of days of
leukopenia (<2,000 WBC/µL) was also significantly reduced.
The maximum tolerated dose of IL-1α was 3 µg/kg/day
Veltri, Smith 194
(approximately 0.075 µg/kg/day). Four out of 18 patients
showed decreases in CA-125 and minor tumor responses after
the first cycle when IL-1α was given alone.
A phase I dose escalation study of IL-1α and high-dose
cyclophosphamide (1.5 g/m2) in patients with advanced can-
cer was conducted by the Eastern Cooperative Oncology
Group and reported by Schuchter et al. to evaluate the myelo-
protective and myelorestorative effects of IL-1 [37]. Three
different schedules of IL-1 in relationship to cyclophos-
phamide were examined. IL-1αwas given i.v. over 15 min for
five days, either prior to cyclophosphamide (day –5 to –1),
overlapping (day –2 to +2), or after cyclophosphamide
(day +1 to +5). There was a significant but transient
increase in WBC 24 h after administration of IL-1, inde-
pendent of IL-1 dose or schedule (reported through the
first two dose levels of 0.03 and 0.06 µg/kg). The overlap-
ping administration of IL-1 and cyclophosphamide was
associated with more severe neutropenia which was dose-
related. No data were reported regarding platelet counts.
Patients are being enrolled onto the next higher dose level
of IL-1, 0.1 µg/kg.
Other investigators have examined the bone marrow
restorative effects of IL-1 with platinum-based chemother-
apy for gynecologic malignancies [38]. Chemotherapy con-
sisting of carboplatin, cyclophosphamide and cisplatin was
first given to patients without IL-1. Cycles 2 and 3 included
IL-1α (Immunex) by s.c. injection at dose levels of 0.3 to
10.0 µg/m2 for four days after chemotherapy. There was no
definite improvement in platelets or neutrophil counts 
comparing cycle 1 to subsequent cycles.
Based on preclinical data that demonstrated IL-1 to have
a radioprotective effect, Wheeler et al. conducted a trial of the
myeloprotective effects of IL-1 given by 4-h i.v. infusion for
four days prior to administration of 131I-labeled CC49 mono-
clonal antibody [39]. This was compared to 15 patients treated
at another institution with radiolabeled CC49 alone and
showed a trend toward reduced nadirs with IL-1 versus
radioimmunotherapy (RIT) alone (WBC 3.1 versus 1.8 × 103,
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Figure 2. Median platelet counts of the groups treated with 0.3 µg per kilogram interleukin 1α after carboplatin ( ) and the control
group (). Carboplatin was administered on day 0. The interleukin 1α-after group received 5 doses of interleukin 1α from day 1 through
day 5. The control group received carboplatin alone.
absolute granulocyte count (AGC) 1.7 versus 0.7 × 103,
platelets 77 versus 46 × 103) but these differences were not
statistically significant. They concluded that pretherapy
with IL-1 did not alter RIT toxicity sufficiently to permit
meaningful dose escalation. 
BONE MARROW TRANSPLANTATION STUDIES
The Medicine Branch of the NCI conducted a study of
IL-1α (Dainippon) as a myeloprotective agent given for seven
days prior to high-dose chemotherapy with ifosfamide, carbo-
platin and etoposide (ICE) followed by autologous bone 
marrow transplant (ABMT) [40, 41]. The IL-1α was given as
a 3-h infusion daily for seven days. The dose of IL-1 was
increased gradually from 0.05 µg/kg up to 0.3 µg/kg on sub-
sequent days of administration. Toxicities observed with the
3-h infusion regimen included hypotension, pulmonary
edema, fever, chills, nausea, vomiting, abdominal pain and
headache. The MTD of IL-1α was 0.2 µg/kg/day. Elevated
levels of IL-6 and G-CSF were detected in 80% of the
patients. IL-1α treatment shortened the durations of granulo-
cytopenia and hospitalization after ABMT, compared to his-
torical controls treated with ICE alone. Although the effect
was statistically significant, it was small. Thrombocytopenia
was not affected in this trial. These findings suggest that
IL-1α has a protective effect for granulocytic precursors when
given before chemotherapy.
Investigators at Duke University have given IL-1β
(OCT-43) following high-dose chemotherapy with cyclophos-
phamide, carboplatin and carmustine (BCNU) with ABMT
[42]. The IL-1α was administered s.c. for seven days over a
range of doses from 0.004 to 0.032 µg/kg. Toxicity from IL-1β
was moderate and consisted of fever, chills, confusion,
hypotension and pain at the injection sites. No significant
effects were noted on recovery of platelets or granulocytes,
although there was a marked increase in the bone marrow
CFU-GM per 105 cells compared to historical controls or
patients who had received G-CSF or GM-CSF.
Weisdorf et al. conducted a phase I/II dose escalation
clinical trial of IL-1α (Immunex) administered after ABMT
in 40 patients with Hodgkin’s disease or non-Hodgkin’s lym-
phoma [43, 44]. IL-1α was given as a daily 6-h i.v. infusion
on days 0 to day +13 at 0.1 to 10 µg/m2/day. Fourteen con-
secutive patients receiving no IL-1α (seven with autologous
bone marrow stem cells and seven with peripheral blood
stem cells) were evaluated as control patients. Toxicity
included fever, severe chills and fatigue. Hypotension was
dose-limiting in both patients receiving 10 µg/m2/day. The
MTD was 3.0 µg/m2/day and led to significantly earlier neu-
trophil recovery (ANC > 500/ml) with a median of 12 days
(range 11 to 27) compared to control patients or patients
receiving 0.1 to 1.0 µg/m2/day of IL-1α (median 27 days;
range 9 to 63). IL-1α patients’ bone marrows were signifi-
cantly enriched with committed myeloid progenitor cells at
day +14. Significant elevations in G-CSF and IL-6 were
detected in the plasma of the IL-1α-treated patients. IL-1α-
treated patients also showed a strong trend toward earlier
freedom from transfusions for red blood cells and platelets.
The earlier hematopoietic engraftment in transplant patients
treated with 3.0 µg/m2/day of IL-1α allowed earlier dis-
charge from the hospital (median 25 versus 37 days for the
control or low-dose IL-1α patients), which resulted in a
median reduction in hospital charges by $38,000.
Nemunaitis et al. conducted a phase I trial of rhIL-1β
(Syntex) in acute myelogenous leukemia (AML) patients
undergoing ABMT (with 4-hydroxycyclophosphamide 
[4-HC]-purged marrow in 9 of the 17 study patients) [45, 46].
All 17 patients received a preparative regimen of busulfan and
cyclophosphamide, and 14 of the 17 patients also received
TBI. The three dose levels of rhIL-1β were 0.01, 0.02 and
0.05 µg/kg/day given by i.v. infusion over 30 min on days 0
to +14. Fevers and chills were noted in all 17 patients within
30 min of initiation of rhIL-1β. Hypotension was noted 5 h to
8 h after rhIL-1β in 14 of the 17 patients, and normal saline or
dopamine was required in 30% of patients to treat hypoten-
sion. Other toxicities included nausea, vomiting, diarrhea,
myalgias and headache. Patients who received rhIL-1β
required fewer days to achieve an ANC > 500/µL compared
to historical controls that did not receive CSFs (25 versus 34
days). The rhIL-1β patients also appeared to have a reduced
incidence of infection between days 0 and +28 (12% versus
23%). Platelet recovery was not different between these AML
study patients and historical controls. Overall two-year sur-
vival was better for rhIL-1β patients compared to historical
control patients (30% versus 20%).
DISCUSSION
IL-1 has the potential to be useful in the treatment of can-
cer based on its direct and indirect antitumor effects and its
hematopoietic effects. The phase I trials noted a variety of tox-
icities consistent with the pleiotropic effects of IL-1. The most
troublesome toxicity that limits utility of IL-1 is hypoten-
sion. The profound hemodynamic effects of IL-1α are sim-
ilar to those noted with other biologic agents, such as
endotoxin, TNF or IL-2. The mechanism for IL-1-induced
hypotension has not been established but could be due to the
induction of prostaglandins E2 or I2 (PGE2, PGI2), prostacy-
clin, platelet-activating factor, TNF or nitric oxide. In the
BRMP studies, IL-1 did not increase TNF levels, and
indomethacin did not decrease the incidence or severity of
hypotension. The delayed and prolonged hypotension, and
the lack of effect of indomethacin are consistent with exper-
iments showing IL-1 to be a potent inhibitor of vascular
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smooth muscle contraction. IL-1 induces production of
nitric oxide which activates guanylate cyclase leading to an
increase in cyclic guanosine monophosphate (GMP), which
then leads to an inhibition of vascular smooth muscle con-
traction [47]. Supporting this mechanism of hypotension is
the finding of significant increases in serum nitrate levels
after IL-1α treatment, especially in patients with more
severe hypotension.
Animal experiments have shown that arginine deriva-
tives can block the enzymatic formation of nitric oxide and
reverse the hypotension induced by TNF and by IL-1 through
the nitric oxide pathway [48, 49]; thus, nitrate antagonists
may be clinically useful for management of hypotension
induced by IL-1. Methylene blue is another agent that
decreases nitrate-induced vasodilation by inhibiting guany-
late cyclase and reducing cyclic GMP levels in smooth mus-
cle. A trial is under way at the BRMP to evaluate methylene
blue to treat hypotension from IL-1. Although changes in
cyclic GMP levels have been observed in patients after meth-
ylene blue treatment, it is too early to assess if this approach
will be successful in ameliorating IL-1 toxicity. All the
hematopoietic effects of IL-1 have been greater with increas-
ing doses of IL-1. Therefore, to maximize its potential utility,
a way of limiting its undesirable toxicity is necessary.
Dose escalation of many chemotherapeutic agents is
limited by granulocytopenia and thrombocytopenia. G-CSF
and GM-CSF do not attenuate thrombocytopenia and permit
only a moderate dose escalation in chemotherapy [50, 51].
Phase I and II studies of IL-1α and IL-1β have demonstrated
that they cause early granulocyte count elevations and
delayed platelet count elevations after treatment. IL-1α also
accelerated the recovery of platelets after high-dose carbo-
platin therapy. The expansion of megakaryocytes (MKs) in
the bone marrow and a dose-related increase in serum levels
of G-CSF and IL-6 have also been noted in clinical trials. A
critical question is whether the beneficial effects of IL-1 can
be replaced by a combination of the cytokines it is known to
induce (G-CSF and IL-6) or whether IL-1 has unique
hematopoietic activities. 
Since IL-1 increases IL-6 levels, increased IL-6 levels
may partially account for increased platelet counts observed
after IL-1 administration. However, in vitro studies have also
demonstrated that IL-1 has more effects on hematopoiesis
than simply increasing IL-6 levels. Bruno and Hoffman [52]
found the addition of IL-1α and IL-6 to CD34+DR+ cultures
resulted in the appearance of CFU-MK-derived colonies,
suggesting that IL-6 required the presence of IL-1α for stim-
ulation of MK colonies. Briddell et al. [53] studied the role
of cytokines in sustaining long-term human megakaryocy-
topoiesis in vitro. They used CD34+DR– cells as the inocu-
lum of cells to initiate long-term bone marrow cultures
(LTBMCs). LTBMCs receiving no cytokines contained no
assayable CFU-MK, no assayable BFU-MK and no observ-
able MKs. These in vitro studies showed that IL-1 can 
activate and expand the number of MK progenitors,
CFU-MK, from primitive CD34+DR– cells. They showed
GM-CSF and IL-3 are each capable of promoting CFU-MK
and BFU-MK, and the action of these cytokines is additive.
Also, IL-1α, but not IL-6, amplifies the ability of IL-3 to pro-
mote the formation of BFU-MK-derived colonies. However,
IL-1α was incapable of promoting BFU-MK-derived colony
formation by itself. Repeat IL-6 additions to LTBMCs led to
mature MKs for only four weeks. Repeat IL-1α or IL-3 addi-
tions to LTBMCs led to mature MKs for eight and 10 weeks.
GM-CSF additions led to MKs for 10 weeks. The addition of
GM-CSF, IL-1α, and IL-3 alone or in combination each led
to the appearance of significant numbers of MKs during
LTBMC. However, IL-6-supplemented cultures led to rela-
tively few MKs — probably because MKs were absent in the
initial CD34+DR– cell population, and IL-6 lacks the ability
to generate these cells from the cellular inoculum. By con-
trast, cultures supplemented with GM-CSF, IL-1α or IL-3
produced greater numbers of MKs, which is consistent with
the primary action of these cytokines being on the CFU-MK
and/or BFU-MK generated from the CD34+DR– cells. IL-6
appears to act as a potent maturation factor acting on more
differentiated megakaryocytic elements. Their results sug-
gest that CD34+DR– cells are capable of initiating long-term
megakaryocytopoiesis in vitro, and that a hierarchy of
cytokines exists capable of sustaining this process.
Ikebuchi et al. [54] have suggested that the synergistic
activities of IL-1 on primitive hematopoietic cells may be
indirect. They analyzed the time courses of colony formation
from cultures of day-2 post-5-FU marrow cells supported by
IL-1α, IL-6, or G-CSF alone or in combination with IL-3. In
the presence of IL-3, both G-CSF and IL-6, but not IL-1α,
hastened the development of colonies and increased the num-
ber of multilineage colonies relative to cultures of IL-3 alone.
Their observations suggest that the synergistic effect of IL-1
is likely due to induction of secondary growth factors, includ-
ing IL-6 and G-CSF, by accessory cells in culture.
The use of IL-1 as a myeloprotective agent was studied
in Hornung’s experiments at the BRMP, which showed that
IL-1 can prevent stem cell depletion in animals undergoing
high-dose chemotherapy in serial passage of marrow exper-
iments [55]. Repetitive treatment using GM-CSF appears to
exhaust the stem cell pool, but IL-1α can protect the bone
marrow from chemotherapy. This could be important with
regard to repetitive high-dose chemotherapy regimens in
curable/treatable malignancies.
The fact that IL-1α did not have a beneficial effect when
given before carboplatin may be due to an insufficient duration
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of IL-1 treatment. Animal studies that demonstrated the mar-
row-protective effects of IL-1α when given before high-dose
cyclophosphamide revealed that IL-1α had no effect when
given by i.v. bolus, but exerted a marked effect when given
intraperitoneally (R. Wiltrout, personal communication).
Therefore, more prolonged i.v. infusion or s.c. administration
of IL-1α before chemotherapy may demonstrate a protective
effect. Preliminary positive results from a trial using a 3-h i.v.
infusion of IL-1α for seven days before high-dose chemother-
apy and ABMT are consistent with the notion that IL-1α could
have a significant myeloprotective effect [40, 41]. However,
the results of other studies argue against any significant myelo-
protective effect of IL-1. Schuchter’s study of IL-1 and cyclo-
phosphamide showed only a transient increase in WBC 24 h
after administration of IL-1 [37]. Wheeler’s study showed
pretherapy IL-1 did not alter RIT toxicity sufficiently to permit
meaningful dose escalation [39]. The results of these clinical
trials support the conclusion that IL-1 is not dramatically
myeloprotective.
Gordon and Hoffman reported that IL-1, IL-6, and KL
(c-kit ligand) can secondarily modulate megakaryocy-
topoiesis by inducing marrow accessory cells to release
hematopoietic growth factors with MK-colony stimulating
activity [56]. They also reported that KL, IL-6, IL-11 and
leukemia inhibitory factor have the ability to promote the
effects of IL-3 on CFU-MK proliferation.
Recently, Kaushansky and Lok reported in vivo results
which strongly suggest that the ligand for c-Mpl is throm-
bopoietin [57, 58]. When the above-listed IL-1 studies were
done, thrombopoietin had not yet been identified.
One of the potential applications of IL-1 is to help
expand bone marrow ex vivo. Studies by Moore et al. [31]
indicate the limited number of pluripotent progenitor cells
in 4-HC purged marrow can be expanded to large numbers
with IL-1 in combination with other cytokines. Also, IL-1
seemed to endow such progenitor cells with responsiveness
to CSFs or IL-3. Synergism between IL-6 and M-CSF or
IL-3 is also seen in the high proliferative potential colony
forming cell assay, and supradditive interactions take place
between IL-1, IL-6, and G-CSF, M-CSF or GM-CSF.
SUMMARY
Over the last six years, many clinical trials of IL-1 have
been conducted. These studies have demonstrated that IL-1
can be safely given to human cancer patients. Toxicities,
although manageable, can be severe. A variety of doses, routes
and schedules of administration has been tested with most tox-
icities and biologic effects being dose-related. By itself, IL-1
has little antitumor activity against melanoma, renal cell carci-
noma, ovarian carcinoma or other diseases, and combinations
with other cytokines or chemotherapy remain to be tested. 
IL-1 has modest hematopoietic effects that may not be
worth the toxicity necessary to achieve them. The best
hematopoietic, especially megakaryocytopoietic, effects will
likely be produced by sequential combinations of cytokines.
The hematopoietic effects of IL-1 do not appear to be unique,
e.g., IL-6 has similar thrombopoietic effects. Although some
researchers have differences of opinion as to whether the
hematopoietic effects of IL-1 are all indirect via induction of
secondary cytokines, these effects can probably be produced
with other cytokines with a more favorable toxicity profile
than IL-1. 
Because of the demonstrated toxicities of IL-1 and the lack
of evidence for unique hematopoietic effects, almost all of the
pharmaceutical companies that make IL-1 plan to discontinue
(or have already discontinued) production of IL-1. For now,
the reality is that IL-1 is not likely to be studied further in phase
III trials. However, IL-1 may have a limited role in expansion
of bone marrow ex vivo following stem cell harvest, which
could allow dose-intensive chemotherapy to be elevated to
new levels in the treatment of curable/treatable types of cancer.
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